Free Trial

Vincerx Pharma (VINC) Competitors

Vincerx Pharma logo
$0.05 -0.01 (-21.77%)
As of 03:05 PM Eastern

VINC vs. NMTR, TRVN, PTPI, SRNE, PBLA, ZVSA, BPTSY, HEPA, VRPX, and VIRX

Should you be buying Vincerx Pharma stock or one of its competitors? The main competitors of Vincerx Pharma include 9 Meters Biopharma (NMTR), Trevena (TRVN), Petros Pharmaceuticals (PTPI), Sorrento Therapeutics (SRNE), Panbela Therapeutics (PBLA), ZyVersa Therapeutics (ZVSA), Biophytis (BPTSY), Hepion Pharmaceuticals (HEPA), Virpax Pharmaceuticals (VRPX), and Viracta Therapeutics (VIRX). These companies are all part of the "pharmaceutical products" industry.

Vincerx Pharma vs. Its Competitors

Vincerx Pharma (NASDAQ:VINC) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and profitability.

In the previous week, Vincerx Pharma's average media sentiment score of 0.00 equaled 9 Meters Biopharma'saverage media sentiment score.

Company Overall Sentiment
Vincerx Pharma Neutral
9 Meters Biopharma Neutral

Vincerx Pharma presently has a consensus price target of $40.00, suggesting a potential upside of 86,856.52%. Given Vincerx Pharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe Vincerx Pharma is more favorable than 9 Meters Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vincerx Pharma
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
9 Meters Biopharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Vincerx Pharma's return on equity of -248.33% beat 9 Meters Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Vincerx PharmaN/A -248.33% -132.73%
9 Meters Biopharma N/A -584.97%-159.45%

44.0% of Vincerx Pharma shares are held by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are held by institutional investors. 15.6% of Vincerx Pharma shares are held by insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Vincerx Pharma is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vincerx PharmaN/AN/A-$40.16M-$20.600.00
9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A

Vincerx Pharma has a beta of 1.72, indicating that its share price is 72% more volatile than the S&P 500. Comparatively, 9 Meters Biopharma has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500.

Summary

Vincerx Pharma beats 9 Meters Biopharma on 10 of the 11 factors compared between the two stocks.

Get Vincerx Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for VINC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VINC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VINC vs. The Competition

MetricVincerx PharmaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$241K$776.90M$5.70B$9.51B
Dividend YieldN/A4.84%4.69%4.01%
P/E Ratio0.001.4028.0720.05
Price / SalesN/A25.35448.5799.42
Price / CashN/A19.5636.2258.56
Price / Book0.006.798.665.87
Net Income-$40.16M-$4.32M$3.25B$258.55M
7 Day PerformanceN/A1.33%4.20%2.23%
1 Month PerformanceN/A3.74%10.82%12.76%
1 Year PerformanceN/A8.18%34.70%19.36%

Vincerx Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VINC
Vincerx Pharma
2.4898 of 5 stars
$0.05
-21.8%
$40.00
+86,856.5%
-99.5%$241KN/A0.0060Gap Down
NMTR
9 Meters Biopharma
N/AN/AN/AN/A$1.04MN/A-0.0220
TRVN
Trevena
1.1692 of 5 stars
$0.91
flat
$5.00
+449.5%
-83.8%$873K$443K-0.0240
PTPI
Petros Pharmaceuticals
N/A$0.03
-2.8%
N/A-99.7%$872K$5.11M-0.0120Gap Down
SRNE
Sorrento Therapeutics
0.4889 of 5 stars
$0.00
-12.5%
N/A-87.0%$772K$60.32M0.00800Gap Down
PBLA
Panbela Therapeutics
0.2989 of 5 stars
$0.16
-1.3%
N/A-59.5%$767KN/A0.006
ZVSA
ZyVersa Therapeutics
0.198 of 5 stars
$0.14
-1.7%
N/A-93.5%$685KN/A0.002Gap Up
BPTSY
Biophytis
N/A$1.81
flat
N/AN/A$634KN/A0.0030
HEPA
Hepion Pharmaceuticals
0.1265 of 5 stars
$0.06
+32.4%
N/A-99.8%$612KN/A-0.0120Gap Up
High Trading Volume
VRPX
Virpax Pharmaceuticals
N/A$0.33
-17.5%
N/A-100.0%$410KN/A0.007Gap Down
VIRX
Viracta Therapeutics
2.5621 of 5 stars
$0.01
flat
$1.75
+17,793.7%
N/A$389KN/A-0.0120

Related Companies and Tools


This page (NASDAQ:VINC) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners